Medical Condition News

RSS

Marshall Edwards initiates ME-344 Phase I trial in solid tumors

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors.

30 May 2012

Scientists develop synthetic peptide that overcomes cancer cells’ survival defenses

Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.

30 May 2012

Link between high levels of PCB and distribution of abdominal fat

There is a correlation between high levels of the environmental toxin PCB and the distribution of body fat to the abdomen. This is shown in a new study published today in the scientific journal Obesity. Abdominal fat is already known to increase the risk of diabetes and high blood pressure, among other conditions.

30 May 2012

Exendin-4 significantly minimizes damage in TBI animal models

Although the death toll is relatively low for people who suffer from traumatic brain injury (TBI), it can have severe, life-long consequences for brain function. TBI can impair a patient's mental abilities, impact memory and behavior, and lead to dramatic personality changes. And long-term medical treatment carries a high economic cost.

30 May 2012

USPTO issues patent to Corgenix’s AspirinWorks technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks technology.

30 May 2012

Positive results from Alkermes’ ALKS 5461 phase 1/2 study on MDD

Alkermes plc today presented positive results from the phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression, in an oral session at the 52nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Phoenix.

30 May 2012

SafeStitch Medical officially changes name of AMID Stapler

SafeStitch Medical, Inc., is pleased to announce that it has officially changed the name of the AMID Stapler to AMID Hernia Fixation Device to better describe the functionalities of the device.

30 May 2012

FDA accepts CSL Behring’s 4-factor PCC BLA for standard review

CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review its Biologics License Application (BLA) for a human 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of vitamin K-antagonist therapy (i.e., warfarin) in patients with acute major bleeding. If approved by the FDA, the CSL Behring 4-factor PCC would be the first agent of its kind available in the United States.

30 May 2012

Possible association between mortality and high levels of vitamin D

Scientists know that Vitamin D deficiency is not healthy. However, new research from the University of Copenhagen now indicates that too high a level of the essential vitamin is not good either. The study is based on blood samples from 247,574 Copenhageners. The results have just been published in the reputed scientific Journal of Clinical Endocrinology and Metabolism.

30 May 2012

EPO issues patent to Cytune’s CYP0150 for treatment of cancer

Cytune Pharma, an emerging leader in innovative immunomodulatory agents against cancer and infectious diseases, announced today that it will attend the BIO2012 to present its major achievements over the last 12 months and to foster partnering discussions.

30 May 2012

Glia seem to play two opposing roles in protecting nerve cells from damage

A protein produced by the central nervous system's support cells seems to play two opposing roles in protecting nerve cells from damage, an animal study by Johns Hopkins researchers suggests: Decreasing its activity seems to trigger support cells to gear up their protective powers, but increasing its activity appears to be key to actually use those powers to defend cells from harm.

30 May 2012

FDA approves RLI’s Absorica to treat severe recalcitrant nodular acne

Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.

30 May 2012

Secreted vesicles play role in spread of cancer

Cancer researchers have known for well over a century that different tumor types spread only to specific, preferred organs. But no one has been able to determine the mechanisms of organ specific metastasis, the so-called "soil and seed" theory of 1889. New details that could help shed light on this hypothesis have been provided by a team of researchers from Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, and their collaborators, proposing a new mechanism controlling cancer metastasis that offers fresh diagnostic and treatment potential.

29 May 2012

Lung in Oncology models for drug discovery launched by PRECOS

Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, has launched its Lung In ONcology model atlas (LION).

29 May 2012

FDA accepts NDA filing for KYNAMRO to treat HoFH

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., announced today that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for KYNAMRO (mipomersen sodium) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).

29 May 2012

Pre-harvest vaccines for management of E. coli in Canadian beef receive favourable conclusion

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a Public Health Agency of Canada study assessing the effects of various interventions on the management of E. coli O157:H7 in Canadian beef came to a favourable conclusion with regard to pre-harvest vaccines such as the Company's Econiche cattle vaccine.

29 May 2012

Diet, activity levels may be improved through mobile technology, remote coaching and financial incentives

The diet and activity levels of patients may be improved through use of mobile technology, remote coaching and financial incentives, according to a report of a randomized controlled trial published in the May 28 issue of Archives of Internal Medicine, a JAMA Network publication.

29 May 2012

Better education early in life may help protect cognitive abilities

Exposure to solvents at work may be associated with reduced thinking skills later in life for those who have less than a high school education, according to a study published in the May 29, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

29 May 2012

Oncos Therapeutics commences clinical study with oncolytic viruses

Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors.

29 May 2012

Spectrum initiates enrollment in RenaZorb Phase 1 trial in healthy volunteers

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced the initiation of patient enrollment in a Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb in healthy volunteers.

29 May 2012